Lupin Limited has announced that it has secured approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The approved product has been deemed bioequivalent to the reference listed drug, Farxiga®, for its approved indications.
The approval marks an important addition to Lupin’s portfolio in the anti-diabetic segment, further strengthening its presence in the United States pharmaceutical market. Dapagliflozin belongs to a class of medications widely prescribed for the management of type 2 diabetes, supporting improved glycemic control and offering additional cardiovascular and renal benefits. With this development, Lupin is positioned to expand access to cost-effective treatment options for patients in the US, while reinforcing its strategy of building a strong generics pipeline in key therapeutic areas.
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with a presence across more than 100 markets worldwide. The company’s portfolio spans branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
The company maintains a strong foothold in both India and the United States, with a diversified presence across multiple therapy segments, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health.
Lupin’s global operations are supported by an extensive manufacturing and research infrastructure, including 15 manufacturing facilities and seven research centers. The company employs a workforce of over 24,000 professionals dedicated to advancing healthcare solutions.
In addition to its core pharmaceutical business, Lupin continues to expand its capabilities through subsidiaries such as Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. These initiatives are aimed at improving patient outcomes through integrated healthcare services and innovative delivery models.
The approval of Dapagliflozin Tablets underscores Lupin’s ongoing commitment to regulatory compliance, quality standards, and expanding access to essential medicines. By strengthening its generics portfolio, the company continues to play a significant role in delivering affordable healthcare solutions to patients globally.